Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Georgetown physician leads national resveratrol study for Alzheimer's disease

14.05.2012
Could a compound found in red wine and red grapes change the course of the illness?

A national, phase II clinical trial examining the effects of resveratrol on individuals with mild to moderate dementia due to Alzheimer's disease has begun as more than two dozen academic institutions recruit volunteers in the coming months. R. Scott Turner, M.D., Ph.D., director of Georgetown University Medical Center's Memory Disorders Program, is the lead investigator for the national study.

Resveratrol is a compound found in red grapes, red grape juice, red wine, chocolate, tomatoes and peanuts. Pre-clinical and pilot clinical research studies suggest that resveratrol may prevent diabetes, act as a natural cancer fighter, ward off cardiovascular disease, and prevent memory loss, but there has been no large definitive study of its effects in humans.

The risk of all of these diseases increases with aging. Animal studies suggest that resveratrol may impede molecular mechanisms of aging. Human population studies suggest several health benefits from modest daily consumption of red wine, but the mechanisms of action in the body are unknown.

"Most resveratrol studies showing any health benefits have been conducted in animal models, such as mice, and with doses that far exceed intake from sipping wine or nibbling on chocolate," says Turner. "With this clinical trial, we'll find out if daily doses of pure resveratrol can delay or alter memory deterioration and daily functioning in people with mild to moderate dementia due to Alzheimer's."

"During this study, we will also test whether resveratrol improves glucose and insulin metabolism in older individuals -- although those who already have diabetes will not be included in this study."

Resveratrol is not approved by the Food and Drug Administration for the treatment of Alzheimer's. It is not known if resveratrol can change the course of the disease.

Not everyone who enrolls in the study will receive resveratrol. Half of the participants will receive a placebo (a sugar pill made to look like the resveratrol pill) to allow researchers to more objectively test the benefits of resveratrol. Neither the patient nor the clinical staff will know if the study participant is receiving the placebo or resveratrol until the end of the study.

"This is the gold-standard for conducting a clinical study because it allows us to objectively determine if resveratrol is offering any benefits," explains Brigid Reynolds, NP, lead investigator for the study at Georgetown.

In addition, the phase II study will examine the safety and tolerability of resveratrol administered twice daily with a dose increase planned at three-month intervals, she says.

According to the National Institute of Aging, more than 5.3 million people in the U.S. are suffering from Alzheimer's, and every 70 seconds, another person develops this disease. In Washington, DC, more than 9,000 people aged 65 and older are currently living with Alzheimer's.

The resveratrol study will be conducted at 26 U.S. academic institutions that are affiliated with the Alzheimer's Disease Cooperative Study. Patients who volunteer for the study cannot be enrolled in another clinical trial during the study period. They will also be asked to abstain from eating or drinking large quantities of foods or beverages that contain resveratrol, and abstain from taking dietary supplements containing resveratrol.

Each patient will be in the study for a twelve-month period and will require a study partner (spouse, friend or caregiver) to visit the Georgetown University Medical Center 10 times over the course of that year. Participants must be willing and able to undergo two lumbar punctures (a procedure where a needle is inserted into the lower spine to collect fluid), three MRI scans of the brain, and blood and urine tests during the course of the study.

The research is sponsored by the Alzheimer's Disease Cooperative Study (ADCS), through a grant from the National Institute on Aging (NIA). Turner and Reynolds report no personal financial interests related to the study.

To learn more about the resveratrol study or other Alzheimer's studies underway at Georgetown, contact Kelly Behan in the GUMC Memory Disorders Program by calling (202) 687-0413 or by emailing her at keb53@georgetown.edu. Information is also available at memory.georgetown.edu. Georgetown study participants must speak English.

About Georgetown University Medical Center

Georgetown University Medical Center is an internationally recognized academic medical center with a three-part mission of research, teaching and patient care (through MedStar Health). GUMC's mission is carried out with a strong emphasis on public service and a dedication to the Catholic, Jesuit principle of cura personalis -- or "care of the whole person." The Medical Center includes the School of Medicine and the School of Nursing & Health Studies, both nationally ranked; Georgetown Lombardi Comprehensive Cancer Center, designated as a comprehensive cancer center by the National Cancer Institute; and the Biomedical Graduate Research Organization (BGRO), which accounts for the majority of externally funded research at GUMC including a Clinical Translation and Science Award from the National Institutes of Health. In fiscal year 2010-11, GUMC accounted for 85 percent of the university's sponsored research funding.

Karen Mallet | EurekAlert!
Further information:
http://www.georgetown.edu

More articles from Studies and Analyses:

nachricht New study: How does Europe become a leading player for software and IT services?
03.04.2017 | Fraunhofer-Institut für System- und Innovationsforschung (ISI)

nachricht Reusable carbon nanotubes could be the water filter of the future, says RIT study
30.03.2017 | Rochester Institute of Technology

All articles from Studies and Analyses >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: A quantum walk of photons

Physicists from the University of Würzburg are capable of generating identical looking single light particles at the push of a button. Two new studies now demonstrate the potential this method holds.

The quantum computer has fuelled the imagination of scientists for decades: It is based on fundamentally different phenomena than a conventional computer....

Im Focus: Turmoil in sluggish electrons’ existence

An international team of physicists has monitored the scattering behaviour of electrons in a non-conducting material in real-time. Their insights could be beneficial for radiotherapy.

We can refer to electrons in non-conducting materials as ‘sluggish’. Typically, they remain fixed in a location, deep inside an atomic composite. It is hence...

Im Focus: Wafer-thin Magnetic Materials Developed for Future Quantum Technologies

Two-dimensional magnetic structures are regarded as a promising material for new types of data storage, since the magnetic properties of individual molecular building blocks can be investigated and modified. For the first time, researchers have now produced a wafer-thin ferrimagnet, in which molecules with different magnetic centers arrange themselves on a gold surface to form a checkerboard pattern. Scientists at the Swiss Nanoscience Institute at the University of Basel and the Paul Scherrer Institute published their findings in the journal Nature Communications.

Ferrimagnets are composed of two centers which are magnetized at different strengths and point in opposing directions. Two-dimensional, quasi-flat ferrimagnets...

Im Focus: World's thinnest hologram paves path to new 3-D world

Nano-hologram paves way for integration of 3-D holography into everyday electronics

An Australian-Chinese research team has created the world's thinnest hologram, paving the way towards the integration of 3D holography into everyday...

Im Focus: Using graphene to create quantum bits

In the race to produce a quantum computer, a number of projects are seeking a way to create quantum bits -- or qubits -- that are stable, meaning they are not much affected by changes in their environment. This normally needs highly nonlinear non-dissipative elements capable of functioning at very low temperatures.

In pursuit of this goal, researchers at EPFL's Laboratory of Photonics and Quantum Measurements LPQM (STI/SB), have investigated a nonlinear graphene-based...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Marine Conservation: IASS Contributes to UN Ocean Conference in New York on 5-9 June

24.05.2017 | Event News

AWK Aachen Machine Tool Colloquium 2017: Internet of Production for Agile Enterprises

23.05.2017 | Event News

Dortmund MST Conference presents Individualized Healthcare Solutions with micro and nanotechnology

22.05.2017 | Event News

 
Latest News

Physicists discover mechanism behind granular capillary effect

24.05.2017 | Physics and Astronomy

Measured for the first time: Direction of light waves changed by quantum effect

24.05.2017 | Physics and Astronomy

Marine Conservation: IASS Contributes to UN Ocean Conference in New York on 5-9 June

24.05.2017 | Event News

VideoLinks
B2B-VideoLinks
More VideoLinks >>>